Ken He Young

Professor

  • 6197 Citations
  • 39 h-Index
20062019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 25 Similar Profiles
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
B-Lymphocytes Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2006 2019

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice

Wang, L., Kumar, M., Deng, Q., Wang, X., Liu, M., Gong, Z., Zhang, S., Ma, X., Xu-Monette, Z., Xiao, M., Yi, Q., Young, K. H., Ramos, K. S. & Li, Y., Jan 1 2019, In : Cancer Letters. 440-441, p. 135-144 10 p.

Research output: Contribution to journalArticle

Plasma Cell Neoplasms
Multiple Myeloma
Blood Cells
Monoclonal Gammopathy of Undetermined Significance
Anemia

Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment

Cai, Q., Fang, Y. & Young, K. H., Mar 1 2019, In : Translational Oncology. 12, 3, p. 523-538 16 p.

Research output: Contribution to journalReview article

Lymphoma
Central Nervous System
Induction Chemotherapy
Genetic Loci
Stem Cell Transplantation
13 Citations (Scopus)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Li, X., Cheng, Y., Zhang, M., Yan, J., Li, L., Fu, X., Zhang, X., Chang, Y., Sun, Z., Yu, H., Zhang, L., Wang, X., Wu, J., Li, Z., Nan, F., Tian, L., Li, W. & Young, K. H., Jan 31 2018, In : Journal of Hematology and Oncology. 11, 1, 15.

Research output: Contribution to journalArticle

T-Cell Lymphoma
Natural Killer T-Cells
Natural Killer Cells
Therapeutics
Non-Hodgkin's Lymphoma
1 Citation (Scopus)

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma

Li, L., Xiao, S., Zhang, L., Li, X., Fu, X., Wang, X., Wu, J., Sun, Z., Zhang, X., Chang, Y., Nan, F., Yan, J., Li, Z., Shi, M., Young, K. H. & Zhang, M., Jan 1 2018, In : Oncotarget. 9, 22, p. 16213-16219 7 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor-2
Protein-Tyrosine Kinases
Non-Hodgkin's Lymphoma
Disease-Free Survival
Lymphoma
12 Citations (Scopus)
Apoptosis
Biological Phenomena
Hematologic Neoplasms
Therapeutics
Drug Resistance